​

Spinal Cord Injury / Phase II

StemCyte is the first hybrid cord blood bank to receive an FDA–approved Phase II clinical trial to treat spinal cord injuries. 

StemCyte's early trials in China were so successful in treating spinal cord injury that the FDA waived the normally required Phase I clinical trial in the U.S., and proceeded to grant StemCyte the approval to start its Phase II clinical trial!  The FDA's confidence in StemCyte's methodologies will speed up the clinical trial process and hopefully culminate in the FDA approving the treatment of spinal cord injury with umbilical cord blood stem cells. StemCyte is honored to receive the FDA's endorsement of our commitment to science excellence. This is the first time that the FDA has waived the need for a Phase I clinical trial in the pursuit of new treatments using UCSC.